verapamil has been researched along with tacrolimus in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (35.71) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, T; Hui, CS; Kitaichi, K; Miyamoto, KI; Sakai, M; Takagi, K; Wang, L; Yokogawa, K | 1 |
| Collett, A; Hallifax, D; Tanianis-Hughes, J; Warhurst, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lieberman, KV; Lin, WG; Reisman, L | 1 |
| Boesch, D; Loor, F; Pourtier-Manzanedo, A | 1 |
| Naito, M; Nishioka, Y; Ogura, T; Sone, S; Tsuruo, T; Yano, S | 1 |
| Rao, US; Scarborough, GA | 1 |
| Heike, Y; Koyama, T; Kuroko, C; Naito, M; Tatsuta, T; Tomida, A; Tsuge, H; Tsuruo, T | 1 |
| Ichimura, K; Kashiwagura, T; Kawahara, K; Koike, M; Matsui, W; Takeguchi, N | 1 |
| Bader, A; Christians, U; Gonschior, AK; Hackbarth, I; Lampen, A; Sewing, KF; von Engelhardt, W | 1 |
| Lay, RH; Medh, RD; Schmidt, TJ | 1 |
| Hauser, IA; Hopfer, U; Koziolek, M; Thévenod, F | 1 |
| Leist, M; Nicotera, P; Volbracht, C | 1 |
| Kato, K; Li, ST; Mikoshiba, K | 1 |
| Benet, LZ; Lantz, MV; Parasrampuria, DA | 1 |
| Berman, B; Ramirez, CC; Villa, AM | 1 |
| Achiwa, K; Aungst, BJ; Kobayashi, M; Oda, M; Saikachi, Y; Saitoh, H; Tadano, K; Takahashi, Y; Yamaguchi, M; Yuhki, Y | 1 |
| Benita, S; Nassar, T; Nyska, A; Rom, A | 1 |
| Swartz, DJ; Urbatsch, IL; Weber, J | 1 |
| Kawamura, A; Nagasaka, Y; Nemoto, H; Oda, K; Usui, T | 1 |
| Baan, CC; Boer, K; De Winter, BCM; Dieterich, M; Francke, MI; Hesselink, DA; Litjens, NHR; Udomkarnjananun, S; van De Velde, D | 1 |
2 review(s) available for verapamil and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel opportunities in the treatment and prevention of scarring.
Topics: Bleomycin; Botulinum Toxins, Type A; Celecoxib; Cicatrix; Fluorouracil; Humans; Immunosuppressive Agents; Laser Therapy; Neuromuscular Agents; Pyrazoles; Sulfonamides; Tacrolimus; Verapamil | 2004 |
26 other study(ies) available for verapamil and tacrolimus
| Article | Year |
|---|---|
Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Membrane; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Immunosuppressive Agents; Leukemia P388; Macrolides; Mice; Neoplasm Transplantation; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Humans; Intestinal Absorption; Mice; Mice, Knockout; Pharmacokinetics; Spectrometry, Mass, Electrospray Ionization | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS).
Topics: Animals; Cyclosporine; Electrophysiology; In Vitro Techniques; Kidney Glomerulus; Rats; Tacrolimus; Verapamil | 1991 |
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro.
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; Cyclosporine; Doxorubicin; Drug Resistance; Leukemia P388; Tacrolimus; Tumor Cells, Cultured; Verapamil; Vincristine | 1991 |
Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Carrier Proteins; Cyclosporine; Cyclosporins; Drug Resistance; Female; Humans; KB Cells; Killer Cells, Natural; Leukemia, Myeloid; Lymphocytes; Membrane Glycoproteins; Monocytes; Neoplasm Proteins; Ovarian Neoplasms; Protein Binding; Tacrolimus; Tumor Cells, Cultured; Verapamil | 1994 |
Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carrier Proteins; Cyclosporins; Humans; Immunosuppressive Agents; In Vitro Techniques; Membrane Glycoproteins; Recombinant Proteins; Tacrolimus; Verapamil | 1994 |
Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Doxorubicin; Drug Resistance; Membrane Glycoproteins; Tacrolimus; Tumor Cells, Cultured; Verapamil | 1993 |
Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Canaliculi; Cyclosporine; Daunorubicin; Drug Resistance; Fluoresceins; Fluorescent Dyes; Fura-2; Liver; Membrane Glycoproteins; Microscopy, Fluorescence; Progesterone; Rats; Signal Processing, Computer-Assisted; Tacrolimus; Verapamil; Vinblastine | 1993 |
Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Gastric Mucosa; Immunosuppressive Agents; Ketoconazole; Oxidoreductases, N-Demethylating; Swine; Tacrolimus; Troleandomycin; Vasodilator Agents; Verapamil | 1996 |
Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants.
Topics: Animals; Corticosterone; Cortodoxone; Cyclosporine; Desoxycorticosterone; Dexamethasone; Genes, Reporter; Glucocorticoids; Hydrocortisone; Immunosuppressive Agents; L Cells; Luciferases; Mice; Polyenes; Quinidine; Receptors, Glucocorticoid; Recombinant Fusion Proteins; Sirolimus; Tacrolimus; Transcription, Genetic; Transfection; Triamcinolone Acetonide; Verapamil | 1998 |
Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Cyclosporine; Endothelium, Vascular; Fluoresceins; Fluorescent Dyes; Humans; Immunohistochemistry; Kidney Tubules; Kinetics; Rats; Tacrolimus; Verapamil | 1998 |
ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation.
Topics: Adenosine Triphosphate; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Carrier Proteins; Caspase 3; Caspase Inhibitors; Caspases; Cerebellum; Colchicine; Cyclosporine; Cysteine Proteinase Inhibitors; Deoxyglucose; Dizocilpine Maleate; Energy Metabolism; Enzyme Activation; Enzyme Inhibitors; Glutathione; Mice; Mice, Inbred BALB C; Microfilament Proteins; Microtubules; Neurons; Neuroprotective Agents; Nitroso Compounds; Nocodazole; Oligopeptides; Paclitaxel; Potassium; Protein Biosynthesis; S-Nitrosoglutathione; Tacrolimus; Verapamil | 1999 |
High Ca(2+)/low Mg(2+) solution induces long-term depression in rat CA1 pyramidal neurons.
Topics: 2-Amino-5-phosphonovalerate; Animals; Benzoates; Calcium; Calcium Channel Blockers; Electric Stimulation; Excitatory Amino Acid Antagonists; Glycine; Hippocampus; In Vitro Techniques; Magnesium; Neuronal Plasticity; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Sirolimus; Solutions; Tacrolimus; Verapamil | 2000 |
A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Separation; Cyclosporine; Enzyme Inhibitors; Fluorescent Dyes; Humans; Immunosuppressive Agents; Lymphocytes; Quinidine; Rhodamine 123; Tacrolimus; Verapamil | 2001 |
Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cardiotonic Agents; Cyclosporine; Digoxin; Immunosuppressive Agents; Intestinal Absorption; Intestine, Small; Jejunum; Methylprednisolone; Progesterone; Rats; Tacrolimus; Verapamil; Vinblastine | 2006 |
A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Carriers; Drug Compounding; Drug Stability; Enterocytes; Humans; Hypromellose Derivatives; In Vitro Techniques; Intestinal Absorption; Intestinal Secretions; Jejunum; Methylcellulose; Microspheres; Nanocapsules; Oils; Polymethacrylic Acids; Rats; Rats, Sprague-Dawley; Solubility; Tacrolimus; Technology, Pharmaceutical; Time Factors; Verapamil | 2008 |
P-glycoprotein is fully active after multiple tryptophan substitutions.
Topics: Adenosine Triphosphatases; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cell Membrane; Crystallography, X-Ray; Cyclosporine; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Humans; Models, Molecular; Molecular Conformation; Mutation; Protein Binding; Saccharomyces cerevisiae; Tacrolimus; Tryptophan; Valinomycin; Verapamil | 2013 |
In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Drug Interactions; Drugs, Investigational; Immunosuppressive Agents; LLC-PK1 Cells; Swine; Tacrolimus; Time Factors; Verapamil | 2014 |
P-glycoprotein, FK-binding Protein-12, and the Intracellular Tacrolimus Concentration in T-lymphocytes and Monocytes of Kidney Transplant Recipients.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Humans; Immunosuppressive Agents; Kidney Transplantation; Monocytes; Rhodamines; T-Lymphocytes; Tacrolimus; Tacrolimus Binding Protein 1A; Transplant Recipients; Verapamil | 2023 |